摘要
目的:探讨酪氨酸激酶抑制剂辅助治疗非小细胞肺癌(NSCLC)的疗效及生存结局的影响。方法:收集在本院接受治疗的非小细胞肺癌患者92例,回顾治疗方式并分为接受常规治疗的对照组50例、接受酪氨酸激酶抑制剂辅助常规治疗的观察组42例。对比治疗前后两组患者的血清恶性分子含量差异,记录治疗后中位生存时间、3年生存率。结果:治疗前,两组血清中肿瘤标志物、血管新生指标、凋亡分子含量差异无统计学意义(P>0.05)。治疗后,观察组血清中肿瘤标志物CYFRA21-1、SCC、ProGRP、CA125的含量低于对照组,血管新生指标VEGF、bFGF、PCDGF的含量低于对照组,ES、PEDF的含量高于对照组,凋亡分子sFas、sFasL的含量高于对照组(P<0.05)。观察组的治疗后中位生存时间长于对照组,3年生存率高于对照组(P<0.05)。结论:酪氨酸激酶抑制剂辅助治疗NSCLC可有效降低肿瘤恶性程度,优化远期生存结局。
Objective：To study the efficacy of adjuvant tyrosine kinase inhibitor therapy for non-small cell lung cancer and its influence on survival outcome.Methods：A total of 92 patients with NSCLC who were treated in our hospital between March 2010 and March 2012 were collected and divided into the control group（n=50）who underwent normal treatment and the observation group（n=42）who underwent adjuvant tyrosine kinase inhibitor therapy＋ routine treatment after the therapies were reviewed.Serum contents of malignant molecules were compared between two groups before and after treatment,and the median survival time after treatment and 3-year survival rate were recorded.Results：Before treatment,differences in serum levels of tumor markers,angiogenesis indexes and apoptosis molecules were not statistically significant between two groups of patients（P〉0.05）.After treatment,serum tumor markers CYFRA21-1,SCC,ProGRP and CA125 levels of observation group were lower than those of control group,angiogenesis indexes VEGF,bFGF and PCDGF levels were lower than those of control group while ES and PEDF levels were higher than those of control group,and apoptosis indexes sFas and sFasL levels were higher than those of control group（P〈0.05）.The median survival time of observation group after treatment was longer than that of control group,and 3-year survival rate was significantly higher than that of control group（P〈0.05）.Conclusions：Adjuvant tyrosine kinase inhibitor therapy for NSCLC can effectively reduce the malignant degree of tumor and optimize the long-term survival outcome.
作者
吴凯
WU Kai(Pharmacy Department, Ya＇an People＇s Hospital in Sichuan Province, Ya＇an 625000, Chin)
出处
《海南医学院学报》
CAS
2017年第12期1693-1696,共4页
Journal of Hainan Medical University
基金
2005年四川省科技攻关计划基金项目(2005sz0951)~~
